Hussein Tawbi, MD, PhD, discusses recent study updates and advances in the treatment of melanoma through the context of two patient cases.
EP. 4: Available First-Line Systemic Therapy Options for Patients With Metastatic Melanoma
October 25th 2023Hussein Tawbi, MD, PhD, explains that for patients with melanoma without a BRAF mutation, first-line therapies primarily include immunotherapy-based (IO) checkpoint inhibitors, with PD-1 inhibitor combination therapies being the current standard of care.
Watch
EP. 5: The Role of Lymphocyte-Activation Gene 3 (LAG-3) in Metastatic Melanoma
November 1st 2023Hussein Tawbi, MD, PhD, explains that LAG-3 is a marker of T-cell exhaustion, and combining LAG-3 inhibitors with PD-1 inhibitors can reverse this exhaustion, enhancing T-cell effectiveness and showing therapeutic benefits in patients with metastatic melanoma.
Watch
EP. 6: Relatlimab/Nivolumab in Metastatic Melanoma: Data From the RELATIVITY-047 Trial
November 1st 2023The RELATIVITY-047 trial evaluated relatlimab and nivolumab versus nivolumab alone in patients with metastatic melanoma, revealing improved progression-free survival, while PDL-1 status wasn't predictive of outcomes.
Watch
EP. 8: Key Trial Data in the Frontline Treatment of Metastatic Melanoma
November 8th 2023Over the past decade, the frontline treatment landscape for metastatic melanoma has evolved with studies like CheckMate-067 and KEYNOTE-006 highlighting the superiority of PD-1-based therapies over ipilimumab, and recent trials introducing new combination treatments.
Watch
Hussein Tawbi, MD, PhD, emphasizes the importance of patient education in managing adverse events from the treatment of metastatic melanoma with checkpoint inhibition, discussing symptom recognition, potential side effects, and treatment adjustments while ensuring team accessibility and patient communication.
Watch
Hussein Tawbi, MD, PhD, explains that for BRAF-mutated metastatic melanoma, treatment options include checkpoint inhibitors, single-agent and combination IO therapies, and BRAF and MEK inhibitor combinations, offering varying response rates and progression-free survival periods.
Watch